Survey of tuberculosis drug resistance among Tibetan refugees in India

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 6, 2014, Pages

  Salvo, F ^a   Dorjee, K ^b   Dierberg, K ^c   Cronin, W ^d   Sadutshang, T D ^b   Migliori, G B ^e   Rodrigues, C ^f   Trentini, F ^g   Di Serio, C ^g   Chaisson, R ^c   Cirillo, D M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Tibetan Delek Hospital   (India)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^e IRCCS   (Italy)

^f P D HINDUJA NATIONAL HOSPITAL   (India)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Drug resistance survey; MDR TB; Tibetan refugees; Tuberculosis in refugees

Indexed keywords

AMINOSALICYLIC ACID; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; DEMOGRAPHY; DRUG SUSCEPTIBILITY TESTING; FEMALE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INDIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; REFUGEE; RISK FACTOR; SOCIOECONOMICS; TIBETAN (PEOPLE); TUBERCULOSIS;

EID: 84901269030     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0516     Document Type: Article

References (29)

1. World Health Organization. Global tuberculosis control: WHO report, 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
2. Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111-119.
3. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO, 2010.
4. Planning Commission, Central Tibetan Administration. Demographic Survey of Tibetans in exile - 2009. Dharamsala, India: CTA, 2010.
5. Nelson L J, Naik Y, Tsering K, Cegielski J P. Population-based risk factors for tuberculosis and adverse outcomes among Tibetan refugees in India, 1994-1996. Int J Tuberc Lung Dis 2005; 9: 1018-1026. (Pubitemid 41549190)
6. Truong D H, Hedemark L L, Mickman J K, Mosher L B, Dietrich S E, Lowry P W. Tuberculosis among Tibetan immigrants from India and Nepal in Minnesota, 1992-1995. JAMA 1997; 277: 735-738. (Pubitemid 27106226)
7. Marras T K, Wilson J, Wang E E, Avendano M, Yang J W. Tuberculosis among Tibetan refugee claimants in Toronto: 1998 to 2000. Chest 2003; 124: 915-921. (Pubitemid 37123309)
8. Lee YA, Munsiff S S, Li J, Driver C R, Mathema B, Kreiswirth B N. Rising number of tuberculosis cases among Tibetans in New York City. J Immigr Health 2001; 3: 173-180. (Pubitemid 33373961)
9. th ed. WHO/HTM/TB/2009.422. Geneva, Switzerland: WHO, 2009.
10. Siddiqi S H, Rüsch-Gerdes S. MGIT procedure manual for BACTEC 307 MGIT 960 TB System. Franklin Lakes, NJ, USA: BD, 2006.
11. Rodrigues C, Jani J, Shenai P, Thakar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the BACTEC MGIT 960 system. Int J Tuberc Lung Dis 2008; 12: 1449-1455.
12. United Nation High Commission for Refugees. Populations of concern to UNHCR. Geneva, Switzerland: UNHCR, 2014. http://www.unhcr.org/50a9f81b27.html. Accessed March 2014
13. nd ed. WHO/HTM/TB/2007.377. Geneva, Switzerland: WHO, 2007.
14. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012; 366: 2161-2170.
15. Falzon D, Gandhi N, Migliori G B, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2013; 42: 156-168.
16. Olson S, English R A, Guenther R S, Claiborne A B; Forum on Drug Discovery, Development, and Translation; Board on Health Sciences Policy; Institute of Medicine. Facing the reality of drug-resistant tuberculosis in India: challenges and potential solutions: summary of a Joint Workshop by the Institute of Medicine, the Indian National Science Academy and the Indian Council of Medical Research. Washington, DC, USA: National Academies Press, 2012.
17. Babu G R, Laxminarayan R. The unsurprising story of MDR-TB resistance in India. Tuberculosis (Edinb) 2012; 92: 301-306.
18. Li D, Wang T, Song X, et al. Genetic study of two single nucleotide polymorphisms within corresponding microRNAs and susceptibility to tuberculosis in a Chinese Tibetan and Han population. Hum Immunol 2011; 72: 598-602.
19. Weyer K, Mirzayev F, Migliori G B, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013; 42: 252-271.
20. Salvo F, Sadutshang T D, Migliori G B, Zumla A, Cirillo D M. Xpert MTB/RIF test for tuberculosis. Lancet 2011; 378: 481-482.
21. Migliori G B, Sotgiu G, Gandhi N R, et al. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur Respir J 2013; 42: 169-79.
22. Ahuja S D, Ashkin D, Avendano M, et al. Multidrug-resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLOS MED 2012; 9: e1001300.
23. Migliori G B, Langendam M W, D'Ambrosio L, et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J 2012; 40: 814-822.
24. Gler M T, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
25. Diacon A H, Dawson R, von Groote-Bidlingmaier F, et al. The 14-day bactericidal activity of combinations of PA-824, bedaquiline, pyrazinamide and moxifloxacin: the path to novel anti-tuberculosis treatment regimens. Lancet 2012; 380: 986-993.
26. De Lorenzo S, Alffenaar J W, Sotgiu G, et al. Efficacy and safety of meropenem/clavunate added to linezolid containing regimens in the treatment of M/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
27. Lee M, Lee J, Carroll M W, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
28. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
29. Alsaad N, van Altena R, Pranger A D, et al. Evaluation of cotrimoxazole in treatment of multidrug-resistant tuberculosis. Eur Respir J 2013; 42: 504-512.